Association of bronchial disease on CT imaging and clinical definitions of chronic bronchitis in a single-center COPD phenotyping study.

Autor: Fat M; Graduate Education, University of California, Los Angeles (UCLA), Los Angeles, CA, USA; Anne Burnett Marion School of Medicine at TCU, Fort Worth, TX, USA., Andersen T; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., Fazio JC; Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., Park SC; Division of Pulmonology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea., Abtin F; Department of Radiology, UCLA, Los Angeles, CA, USA., Buhr RG; Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., Phillips JE; Inflammation Discovery Research, Amgen, Thousand Oaks, CA, USA., Belperio J; Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., Tashkin DP; Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., Cooper CB; Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Exercise Physiology Research Laboratory, Department of Physiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., Barjaktarevic I; Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address: IBarjaktarevic@mednet.ucla.edu.
Jazyk: angličtina
Zdroj: Respiratory medicine [Respir Med] 2024 Sep; Vol. 231, pp. 107733. Date of Electronic Publication: 2024 Jul 08.
DOI: 10.1016/j.rmed.2024.107733
Abstrakt: Introduction: Chronic Bronchitis (CB) represents a phenotype of chronic obstructive pulmonary disease (COPD). While several definitions have been used for diagnosis, the relationship between clinical definitions and radiologic assessment of bronchial disease (BD) has not been well studied. The aim of this study was to evaluate the relationship between three clinical definitions of CB and radiographic findings of BD in spirometry-defined COPD patients.
Methods: A cross-sectional analysis was performed from a COPD phenotyping study. It was a prospective observational cohort. Participants had spirometry-defined COPD and available chest CT imaging. Comparison between CB definitions, Medical Research Council (CB MRC ), St. George's Respiratory Questionnaire (CB SGRQ ), COPD Assessment Test (CB CAT ) and CT findings were performed using Cohen's Kappa, univariate and multivariate logistic regressions.
Results: Of 112 participants, 83 met inclusion criteria. Demographics included age of 70.1 ± 7.0 years old, predominantly male (59.0 %), 45.8 ± 30.8 pack-year history, 21.7 % actively smoking, and mean FEV 1 61.5 ± 21.1 %. With MRC, SGRQ and CAT definitions, 22.9 %, 36.6 % and 28.0 % had CB, respectively. BD was more often present in CB compared to non-CB patients; however, it did not have a statistically significant relationship between any of the CB definitions. CB SGRQ had better agreement with radiographically assessed BD compared to the other two definitions.
Conclusion: Identification of BD on CT was associated with the diagnoses of CB. However, agreement between imaging and definitions were not significant, suggesting radiologic findings of BD and criteria defining CB may not identify the same COPD phenotype. Research to standardize imaging and clinical methods is needed for more objective identification of COPD phenotypes.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: DPT has consulted with AstraZeneca, Sunovion, Mylan and Theravance. RGB reports personal consulting fees from Theravance Biopharma/Mylan and GlaxoSmithKline. JEP is employed by AMGEN. CBC reports grants from NIH/NHLBI, NIH Foundation and the COPD Foundation, during the conduct of the study; he also reports personal fees from AstraZeneca, GlaxoSmithKline, Chiesi, NUVAIRA, MGC Diagnostics, Horizon Therapeutics, Respiree, Herbalife, Verona, RS BioTherapeutics, Genentec and Cambridge University Press, outside the submitted work. IZB has consulted with Astra Zeneca, Grifols, Verona Pharma, Takeda, Sanofi/Regeneron, Inhibrx and has received funding from Viatris, Theravance, AMGEN, Takeda and Aerogen. MF, TA, JCF, SCP, FA, and JB have no reportable disclosures.
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: